COVID-19 Vaccination Strategy in China: A Case Study.

Epidemiolgia (Basel, Switzerland) Pub Date : 2021-09-03 DOI:10.3390/epidemiologia2030030

Marjan Mohamadi, Yuling Lin, Mélissa Vuillet Soit Vulliet, Antoine Flahault, Liudmila Rozanova, Guilhem Fabre

{"title":"COVID-19 Vaccination Strategy in China: A Case Study.","authors":"Marjan Mohamadi, Yuling Lin, Mélissa Vuillet Soit Vulliet, Antoine Flahault, Liudmila Rozanova, Guilhem Fabre","doi":"10.3390/epidemiologia2030030","DOIUrl":null,"url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines.</p>","PeriodicalId":72944,"journal":{"name":"Epidemiolgia (Basel, Switzerland)","volume":"2 3","pages":"402-425"},"PeriodicalIF":0.0000,"publicationDate":"2021-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620874/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiolgia (Basel, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/epidemiologia2030030","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with 483.34 million doses having been administered across the country by 21 May 2021. China is also acting as an important player in the development and production of SARS-CoV-2 vaccines.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

中国的 COVID-19 疫苗接种策略：案例研究。

中国 2019 年冠状病毒病（COVID-19）疫情于 2019 年 12 月 8 日前后正式发现首例病例，并于 2019 年 12 月 31 日首次向世界卫生组织报告。然而，一名 55 岁感染者的病例可能可以追溯到 11 月 17 日。疫情蔓延迅速，种类繁多。对经济、政治和社会的影响还为时不远。本文以国内外数据库中的英文、法文和中文研究为基础，旨在通过疫情管理和中国的疫苗接种应对策略来研究 COVID-19 在中国的情况。中国通过非药物干预措施控制了冠状病毒病的流行，并启动了大规模疫苗接种计划以进一步预防疾病，截至 2021 年 5 月 21 日，全国已接种 4.8334 亿剂疫苗，接种工作稳步推进。中国还在开发和生产 SARS-CoV-2 疫苗方面发挥了重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊